Primary immunodeficiency diseases (pid) Trials in Dallas, United States
Conditions / Primary immunodeficiency diseases (pid) / Dallas, United States
Clinical trials for Primary immunodeficiency diseases (pid) investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00157079 | Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders | COMPLETED | PHASE3 |
| NCT00546871 | Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects | COMPLETED | PHASE2/PHASE3 |
| NCT02593188 | Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) | COMPLETED | — |
| NCT00782106 | Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously | COMPLETED | PHASE1/PHASE2 |
| NCT05755035 | A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases | COMPLETED | PHASE2/PHASE3 |
| NCT03277313 | Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects | COMPLETED | PHASE3 |
| NCT06076642 | A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases | RECRUITING | PHASE3 |
| NCT00814320 | Gammagard Liquid and rHuPH20 in PID | COMPLETED | PHASE3 |
| NCT01218438 | Phase 2/3 Study of IGSC, 20% in PIDD | COMPLETED | PHASE2/PHASE3 |
| NCT01175213 | Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID | COMPLETED | PHASE3 |